Category

Posters

[article_filters]

Development of a culture manufacturing process preserving the profile of gut microbiota for therapeutic purposes

novembre 13, 2022

Pooling of faecal material results in standardized and high-richness microbiotherapy products MaaT013 and MaaT033

novembre 13, 2022

Pooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease: results from the phase IIa HERACLES study and expanded access program

novembre 13, 2022

Communiqués de presse, Posters

MaaT Pharma annonce la publication dans Nature Communications des résultats de l’essai clinique ODYSSEE de Phase 1/2.

mai 25, 2021

EBMT 2020: Successful and safe treatment of intestinal Graft-versus-Host Disease (GvHD) with pooled-donor full ecosystem microbiota therapeutics

août 28, 2020

ASH 2019: Successful and safe treatment of intestinal Graft-versus-Host Disease (GvHD) with pooled-donor full ecosystem microbiota therapeutics

décembre 7, 2019

An evaluation of binning methods to recover human gut microbial pan-genomes from non-redundant reference gene catalog

juillet 24, 2019

HERACLES: A Phase II single-arm prospective study to assess the efficacy of Fecal Microbiota Transfer (FMT) in the treatment of steroid-refractory gastro-intestinal predominant aGVHD post allo-hsct

juin 1, 2019

ASH 2018: The Odyssee study: Results of a prospective multicenter trial

décembre 2, 2018

EMBL: Developing a New Generation of First-in-class High Diversity Microbiome Biotherapeutics to Treat Life-threatening Diseases

septembre 18, 2018

We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.

COMPANY

Ressources

Contact

We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.

COMPANY

Ressources

Contact